SCHEDULE: Goldman Sachs Discloses Stake in Seaport Therapeutics

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 5.5% of Seaport Therapeutics, Inc.'s voting common stock as of May 6, 2026.

Summary

• This filing is a Schedule 13G, indicating that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC beneficially own 2,791,814 shares of Seaport Therapeutics, Inc. common stock.
• This ownership represents 5.5% of the total class of securities.
• The filing date for this event is May 6, 2026.
• Goldman Sachs & Co. LLC is identified as a broker-dealer, options/odd-lot dealer, and investment adviser.
• The Goldman Sachs Group, Inc. is identified as a holding company.
• A joint filing agreement is in place between The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.
• Powers of Attorney have been granted to various individuals to execute and deliver required filings.
• The filing clarifies that beneficial ownership is attributed to certain operating units of The Goldman Sachs Group, Inc. and its subsidiaries, disclaiming ownership for client accounts or other investment entities where discretion is limited or held by others.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership by a financial institution and does not provide performance data or strategic insights into Seaport Therapeutics, Inc.

Positives

• Goldman Sachs, a major financial institution, has taken a significant stake in Seaport Therapeutics, potentially signaling confidence in the company's prospects.
• The filing is a routine disclosure for significant beneficial ownership, indicating transparency in the market.

Negatives

• The filing does not provide any financial performance data for Seaport Therapeutics, Inc., only ownership information.
• The nature of the beneficial ownership is complex, with disclaimers regarding client accounts and other investment entities, which may obscure the ultimate beneficial holders.

Risks

• The filing does not explicitly mention any risks associated with Seaport Therapeutics, Inc. or the investment itself.
• Potential for increased market volatility in Seaport Therapeutics' stock due to the disclosure of a significant institutional holder.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Seaport Therapeutics, Inc. It solely pertains to the ownership stake held by Goldman Sachs entities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by major financial institutions like Goldman Sachs often indicate significant investment activity or strategic interest in a particular company or sector. This filing suggests Goldman Sachs views Seaport Therapeutics, Inc. as a noteworthy entity within its investment portfolio, though the specific reasons for this stake are not detailed.

Stakeholder Impact

• Shareholders of Seaport Therapeutics, Inc.: The disclosure of a significant stake by a major financial institution like Goldman Sachs could be perceived positively, potentially increasing investor confidence. However, without further context, the direct impact on share price is uncertain.
• Competitors of Seaport Therapeutics, Inc.: The involvement of a large institutional investor may signal increased competition or strategic shifts within the industry.
• The broader investment community: This filing contributes to market transparency regarding significant ownership positions.

Next Steps

• Monitor future filings by Seaport Therapeutics, Inc. for financial performance and strategic updates.
• Observe any further disclosures from Goldman Sachs regarding their investment in Seaport Therapeutics, Inc.

Key Dates

Keywords

Schedule 13G, Seaport Therapeutics, The Goldman Sachs Group, Inc., Goldman Sachs & Co. LLC, Beneficial Ownership, Common Stock, SEC Filing, Investment, Financial Institution